What began in early 2025 as a transformational transaction for Mayne Pharma has, by December, unravelled into a public dispute over obligations, regulatory conditions, and the future of the companies’ long-negotiated scheme of arrangement.
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep.25
July 24, 2026 - - Podcast -
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News

